检验医学与临床2025，Vol.22Issue(23)：3174-3180,7.DOI:10.3969/j.issn.1672-9455.2025.23.002
贝伐珠单抗与奥希替尼联合用于ⅠB～ⅢA期非小细胞肺癌患者术后辅助治疗中的效果及对cGAS/STING信号通路因子的影响
Effect of bevacizumab combined with osimertinib in the adjuvant treatment of patients with stage ⅠB-ⅢA non-small cell lung cancer and its effect on cGAS/STING signaling pathway factors
摘要
Abstract
Objective To investigate the effect of bevacizumab combined with osimertinib in the adjuvant treatment of patients with stage ⅠB-ⅢA non-small cell lung cancer(NSCLC)and its effect on cyclic guany-late adenylate synthase(cGAS)/stimulator of interferon gene(STING)signaling pathway factors.Methods A total of 122 patients with stage ⅠB-ⅢA NSCLC admitted to the hospital from January 2019 to June 2021 were selected as the research objects.According to the random number table method,they were di-vided into study group and control group,with 61 cases in each group.All patients were given conventional chemotherapy,the control group was given osimertinib on the basis of conventional chemotherapy,and the study group was given bevacizumab on the basis of the control group.The tumor markers[carcinoembryonic antigen(CEA),neural enolase(NSE),carbohydrate antigen 125(CA125),carbohydrate antigen 199(CA199)],growth factors[epidermal growth factor receptor(EGFR),connective tissue growth factor(CT-GF),vascular endothelial growth factor(VEGF),transforming growth factor-β1(TGF-β1),cGAS/STING signaling pathway factor levels,quality of life(including lung cancer specific module symptoms,functional sta-tus,physical status,social/family status and emotional status scores)score and adverse reactions were com-pared between the two groups before and after treatment.The patients were followed up for 3 years,and the 3-year survival rate of the two groups was calculated.Kaplan-Meier survival curve was used to analyze the 3-year survival of the observation group and the control group.Results After 4 cycles of treatment,the levels of serum CEA,NSE,CA125,CA199,EGFR,VEGF,CTGF,TGF-β1,cGAS mRNA and STING mRNA in the two groups were lower than those before treatment,and those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).The scores of lung cancer specific module symptoms,functional status,physical status,social/family status and emotional status in the two groups were higher than those before treatment,and those in the study group were higher than those in the control group,and the differences were statistically significant(P<0.05).There was no significant difference in gastrointestinal reaction,leukopenia,oral mucositis,bone marrow suppression,peripheral nerve and other adverse reactions between the two groups(P>0.05).After 3 years of follow-up,4 cases in the study group and 3 cases in the control group were lost to follow-up.The 3-year survival rate of the study group was 87.72%(50/57),which was higher than 72.41%(42/58)of the control group,and the difference was statisti-cally significant(χ2=4.209,P=0.040).Kaplan-Meier survival curve analysis showed that the overall surviv-al curve of the study group was better than that of the control group(Log-rankχ2=4.250,P=0.039).Con-clusion Osimertinib combined with bevacizumab in the postoperative adjuvant treatment of stage ⅠB-ⅢA NSCLC can control the tumor development,prolong the survival time and improve the quality of life.关键词
非小细胞肺癌/胸腔镜根治术/奥希替尼/贝伐珠单抗/生长因子/生存质量/肿瘤标志物/cGAS/STINGKey words
non-small cell lung cancer/thoracoscopic radical resection/osimertinib/bevacizumab/growth factor/quality of life/tumor marker/cGAS/STING分类
医药卫生引用本文复制引用
刘雨鑫,周小伟,雷蕾,杨林琪,万志渝..贝伐珠单抗与奥希替尼联合用于ⅠB～ⅢA期非小细胞肺癌患者术后辅助治疗中的效果及对cGAS/STING信号通路因子的影响[J].检验医学与临床,2025,22(23):3174-3180,7.基金项目
2020年四川省医学(青年创新)科研项目(S201249). （青年创新）
